Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of Xywav™ Oral Solution in Adult Patients with Idiopathic Hypersomnia
Jazz Pharmaceuticals announces a new collaborative relationship with the American Heart Association to address heart disease in sleep disorders.